Syndax Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update

$SNDX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $SNDX alert in real time by email
8-K
0001395937false00013959372024-12-202024-12-20

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 20, 2024

 

 

SYNDAX PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37708

32-0162505

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

Building D

Floor 3

35 Gatehouse Drive

 

Waltham, Massachusetts

 

02451

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (781) 419-1400

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock

 

SNDX

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 20, 2024, Syndax Pharmaceuticals, Inc. (the “Company”) announced that it has eliminated the Chief Medical Officer position and that Catherine Madigan, M.D. will cease to serve as the Company’s Chief Medical Officer and as an employee of the Company effective as of December 20, 2024. Dr. Madigan will receive severance compensation consistent with the terms of her service agreement, as described in Exhibits 10.24 and 10.25 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

SYNDAX PHARMACEUTICALS, INC.

 

 

 

 

Date:

December 20, 2024

By:

/s/ Michael A. Metzger

 

 

 

Michael A. Metzger
Chief Executive Officer

 


Get the next $SNDX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SNDX

DatePrice TargetRatingAnalyst
10/24/2024$37.00Buy
UBS
6/28/2024$37.00Buy
Jefferies
1/31/2024$36.00 → $23.00Sector Outperform → Sector Perform
Scotiabank
12/22/2023$45.00Buy
Mizuho
10/25/2023$29.00Buy
BofA Securities
10/11/2023$30.00Buy
Goldman
7/27/2023Sector Outperform
Scotiabank
7/11/2023$40.00Buy
Guggenheim
More analyst ratings

$SNDX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on March 1, 2025 the Company granted inducement awards to purchase up to 282,000 shares of common stock to 12 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting

    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    – $7.7 million in Revuforj® (revumenib) net product revenue in initial five weeks of launch – – Launched Niktimvo™ (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte – – sNDA filing for revumenib in R/R mNPM1 AML expected in 2Q25 based on positive pivotal data from AUGMENT-101 trial – – $692.4 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 8:00 a.m. ET – NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its finan

    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Syndax Announces Participation in March Investor Conferences

    WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference in Boston, MA, with a fireside chat on Tuesday, March 4, 2025, at 3:10 p.m. ETBarclays 27th Annual Global Healthcare Conference in Miami Beach, FL, with a fireside chat on Thursday, March 13, 2025, at 8:30 a.m. ET A live webcast of the fireside chats will be available

    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$SNDX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$SNDX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$SNDX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SNDX
SEC Filings

See more

$SNDX
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • FDA Approval for REVUFORJ issued to SYNDAX PHARMACEUTICALS INC

    Submission status for SYNDAX PHARMACEUTICALS INC's drug REVUFORJ (ORIG-1) with active ingredient REVUMENIB has changed to 'Approval' on 11/15/2024. Application Category: NDA, Application Number: 218944, Application Classification: Type 1 - New Molecular Entity

    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$SNDX
Leadership Updates

Live Leadership Updates

See more
  • Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

    BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) since 2015. "We are delighted to have Michael, a proven leader in our industry with a robust track record of success, join the board," said Lara S. Sullivan, M.D., President and Chief Ex

    $PYXS
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors

    WALTHAM, Mass., May 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Aleksandra Rizo, M.D., Ph.D., to its Board of Directors. Dr. Rizo has extensive clinical development experience and a track record of successfully leading the development of several hematology drugs from discovery through commercialization. She will serve as a member of the Science and Technology Committee of the Board. Dr. Rizo will replace Dr. Briggs Morrison who will step down effective May 14, 2024 after a successful 9-year tenure as a member of the Company's Board of Directo

    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

    VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Dr. Neil Gallagher to its board of directors effective April 2, 2024. "Dr. Gallagher is the sixth director to join our board of directors in the past twelve months as we continue to refresh and strengthen the Board governance and oversight required for the next stage of the Company's development and growth," said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. "His exp

    $SNDX
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

$SNDX
Financials

Live finance-specific insights

See more
  • Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    – $7.7 million in Revuforj® (revumenib) net product revenue in initial five weeks of launch – – Launched Niktimvo™ (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte – – sNDA filing for revumenib in R/R mNPM1 AML expected in 2Q25 based on positive pivotal data from AUGMENT-101 trial – – $692.4 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 8:00 a.m. ET – NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its finan

    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

    WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and full year 2024 financial results and provide a business update on Monday, March 3, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 8:00 a.m. ET on Monday, March 3, 2025 to discuss the Company's financial results and provide a business update. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section o

    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial

    – Subgroup analyses from Ph 2 protocol-defined R/R mNPM1 AML efficacy population (N=64) show responses across all major subgroups, including heavily pretreated patients – – 26% CR+CRh (20/77) and 48% ORR (37/77) in all enrolled patients who met the efficacy evaluable criteria in Ph 2 R/R mNPM1 AML cohort – – 100% ORR (37/37) and 95% CRc (35/37) in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly diagnosed mNPM1 or KMT2Ar AML – – BEAT AML data highlight the potential for revumenib to advance the current standard of care – WALTHAM, Mass., Dec. 9, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company develop

    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$SNDX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more